PMID- 19505401
OWN - NLM
STAT- MEDLINE
DCOM- 20090723
LR  - 20170214
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 22
IP  - 2
DP  - 2009 Apr-Jun
TI  - The role of interleukin-6 and transforming growth factor-beta1 in predicting 
      restenosis within stented infarct-related artery.
PG  - 493-500
AB  - Despite high efficacy of percutaneous coronary intervention (PCI), in-stent 
      restenosis proves to be a significant problem of therapy. Restenosis concerns 
      around 30 percent of patients. Studies have suggested that restenosis is 
      initiated by cells which participate in intense inflammatory reaction caused by 
      stent implantation. Atherosclerotic plaque rupture during stent implantation and 
      PCI-associated injury of the vessel wall lead to hemorrhage and release of 
      various cytokines. They are probably responsible for quick recurrence of vascular 
      lumen stenosis (restenosis). Interleukin-6 (IL-6) is known as a main 
      pro-inflammatory cytokine, whereas Transformig Growth Factor-beta1 (TGF-beta1) 
      has anti-inflammatory properties. The study population comprised 36 patients with 
      myocardial infarction treated with PCI with stent implantation. They underwent 
      control coronary angiography after 12 months. At this time plasma concentration 
      of IL-6 and TGF-beta was measured in peripheral blood. Serum IL-6 concentration 
      in the analyzed population correlates with lumen loss (p<0.01) and the severity 
      of stenosis (p<0.001). No such correlation was found between serum TGF-beta1 
      concentration and lumen loss (p=NS) or the severity of stenosis (p=NS). The IL-6 
      plasma concentration may be a marker of in-stent restenosis in patients after 
      PTCA, while the concentration of TGF-beta1 is not associated with the occurrence 
      of restenosis at one year of follow-up.
FAU - Szkodzinski, J
AU  - Szkodzinski J
AD  - 3rd Dept. of Cardiology, Silesian Medical University, Zabrze, Poland. 
      bartekh@mp.pl
FAU - Blazelonis, A
AU  - Blazelonis A
FAU - Wilczek, K
AU  - Wilczek K
FAU - Hudzik, B
AU  - Hudzik B
FAU - Romanowski, W
AU  - Romanowski W
FAU - Gasior, M
AU  - Gasior M
FAU - Wojnar, R
AU  - Wojnar R
FAU - Lekston, A
AU  - Lekston A
FAU - Polonski, L
AU  - Polonski L
FAU - Zubelewicz-Szkodzinska, B
AU  - Zubelewicz-Szkodzinska B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
RN  - 0 (Biomarkers)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*adverse effects/instrumentation
MH  - Biomarkers/blood
MH  - Coronary Angiography
MH  - Coronary Restenosis/diagnostic imaging/etiology/*immunology
MH  - Coronary Vessels/*immunology/pathology
MH  - Female
MH  - Humans
MH  - Interleukin-6/*blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*therapy
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Stents
MH  - Time Factors
MH  - Transforming Growth Factor beta1/*blood
MH  - Treatment Outcome
EDAT- 2009/06/10 09:00
MHDA- 2009/07/25 09:00
CRDT- 2009/06/10 09:00
PHST- 2009/06/10 09:00 [entrez]
PHST- 2009/06/10 09:00 [pubmed]
PHST- 2009/07/25 09:00 [medline]
AID - 26 [pii]
AID - 10.1177/039463200902200226 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):493-500. doi: 
      10.1177/039463200902200226.